3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with Movement Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fundke, R; Hesse, S; Kendziorra, K; Meyer, PT; Oehlwein, C; Sabri, O; Sattler, B; Schaefer, WM; Winz, OH | 1 |
| Hondl, N; Ladurner, G; Staffen, W; Trinka, E; Zenzmaier, R | 1 |
2 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and Movement Disorders
| Article | Year |
|---|---|
Kinetic analyses of [123I]IBZM SPECT for quantification of striatal dopamine D2 receptor binding: a critical evaluation of the single-scan approach.
Topics: Adult; Aged; Benzamides; Corpus Striatum; Female; Humans; Kinetics; Male; Metabolic Clearance Rate; Middle Aged; Movement Disorders; Protein Binding; Pyrrolidines; Radiopharmaceuticals; Receptors, Dopamine D2; Tomography, Emission-Computed, Single-Photon | 2008 |
SPET investigations in extrapyramidal diseases using specific ligands.
Topics: Adult; Aged; Benzamides; Brain; Cocaine; Dopamine Antagonists; Hepatolenticular Degeneration; Humans; Huntington Disease; Iodine Radioisotopes; Male; Middle Aged; Movement Disorders; Parkinson Disease; Pyrrolidines; Receptors, Dopamine D2; Reference Values; Supranuclear Palsy, Progressive; Tissue Distribution; Tomography, Emission-Computed, Single-Photon | 1997 |